Choosing BTK Inhibitors as Treatment for Relapsed Mantle Cell Lymphoma

When deciding between rechallenging with standard chemotherapy or opting for a BTK inhibitor as second-line treatment for relapsed mantle cell lymphoma, the use of a BTK inhibitor is generally favored. The BTK inhibitor of choice will depend on available options, with perturbtinib showing promising results in terms of tolerability and efficacy. However, considering other treatment options such as allogeneic transplant and CAR-T cell therapy, as well as enrolling patients in clinical trials, should also be considered in the overall treatment plan.